Skip to main content
Top
Published in: International Urology and Nephrology 3/2013

01-06-2013 | Urology-Original Paper

Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia

Authors: Minki Baek, Jung Yoon Kang, Jeongyun Jeong, Dae Kyung Kim, Kwang Myung Kim

Published in: International Urology and Nephrology | Issue 3/2013

Login to get access

Abstract

Purpose

We investigated the treatment outcomes according to neuropathic bladder sphincter dysfunction (NBSD) type after oral oxybutynin (OBT) treatment in children with NBSD caused by myelodysplasia.

Methods

Among 334 pediatric patients who were diagnosed with NBSD caused by myelodysplasia, only children treated with oral OBT for more than 1 year with pre- and post-treatment urodynamic studies and dimercaptosuccinic acid (DMSA) were retrospectively reviewed. We compared pre- and post-treatment urodynamic parameters including maximum cystometric capacity (MCC), MCC/estimated bladder capacity (EBC), and compliance by NBSD type in children. We also compared renal scarring on pre- and post-treatment DMSA by NBSD type in children.

Results

Our study population was comprised of 81 children (45 boys and 36 girls), with a mean age of 4.2 ± 3.4 years. The mean follow-up duration was 4.5 (range 1.0–15.1) years. After OBT treatment, MCC was increased significantly in all types of NBSD from 110.3 ± 62.2 to 202.3 ± 103.9 ml (p < 0.05), compliance was significantly improved from 6.4 ± 6.1 to 11.1 ± 9.6 ml/cmH2O (p < 0.05), but MCC/EBC was slightly decreased from 75.2 ± 46.9 to 69.8 ± 33.3 % (p = 0.40). Sub-analyzed by NBSD type, the pre-treatment compliance of children with acontractile detrusor with spastic sphincter (n = 16) was markedly decreased compared with other types of NBSD. Acontractile detrusor with spastic sphincter demonstrated the worst renal deterioration on DMSA.

Conclusions

Although increases in MCC/EBC were limited, oral OBT treatment markedly improved MCC and compliance in all NBSD types. Children who had acontractile detrusor with spastic sphincter had a relatively high probability of renal deterioration and required specific attention.
Literature
2.
go back to reference Bauer SB, Joseph DB (1990) Management of the obstructed urinary tract associated with neurogenic bladder dysfunction. Urol Clin North Am 17:395–406PubMed Bauer SB, Joseph DB (1990) Management of the obstructed urinary tract associated with neurogenic bladder dysfunction. Urol Clin North Am 17:395–406PubMed
3.
go back to reference Baskin LS, Kogan BA, Benard F (1990) Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. Br J Urol 66:532–534PubMedCrossRef Baskin LS, Kogan BA, Benard F (1990) Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. Br J Urol 66:532–534PubMedCrossRef
4.
go back to reference Fernandes ET, Reinberg Y, Vernier R, Gonzalez R (1994) Neurogenic bladder dysfunction in children: review of pathophysiology and current management. J Pediatr 124:1–7PubMedCrossRef Fernandes ET, Reinberg Y, Vernier R, Gonzalez R (1994) Neurogenic bladder dysfunction in children: review of pathophysiology and current management. J Pediatr 124:1–7PubMedCrossRef
6.
go back to reference Madersbacher H, Murtz G, Alloussi S, Domurath B, Henne T, Korner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G (2009) Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int 103:776–781. doi:10.1111/j.1464-410X.2008.08093.x PubMedCrossRef Madersbacher H, Murtz G, Alloussi S, Domurath B, Henne T, Korner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G (2009) Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int 103:776–781. doi:10.​1111/​j.​1464-410X.​2008.​08093.​x PubMedCrossRef
11.
go back to reference Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, Mandell J, Colodny AH, Retik AB (1995) The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 154:1500–1504PubMedCrossRef Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, Mandell J, Colodny AH, Retik AB (1995) The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 154:1500–1504PubMedCrossRef
12.
go back to reference Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB (1999) Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. J Urol 162:1068–1071PubMedCrossRef Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB (1999) Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. J Urol 162:1068–1071PubMedCrossRef
14.
15.
go back to reference Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, Jorgensen TM, Rittig S, Walle JV, Yeung CK, Djurhuus JC (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol 176:314–324. doi:10.1016/s0022-5347(06)00305-3 PubMedCrossRef Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, Jorgensen TM, Rittig S, Walle JV, Yeung CK, Djurhuus JC (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol 176:314–324. doi:10.​1016/​s0022-5347(06)00305-3 PubMedCrossRef
16.
go back to reference Fairhurst JJ, Rubin CM, Hyde I, Freeman NV, Williams JD (1991) Bladder capacity in infants. J Pediatr Surg 26:55–57PubMedCrossRef Fairhurst JJ, Rubin CM, Hyde I, Freeman NV, Williams JD (1991) Bladder capacity in infants. J Pediatr Surg 26:55–57PubMedCrossRef
19.
go back to reference Goessl C, Sauter T, Michael T, Berge B, Staehler M, Miller K (2000) Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 55:414–418PubMedCrossRef Goessl C, Sauter T, Michael T, Berge B, Staehler M, Miller K (2000) Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 55:414–418PubMedCrossRef
20.
21.
go back to reference Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW (2003) Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78:696–702. doi:10.4065/78.6.696 PubMedCrossRef Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW (2003) Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78:696–702. doi:10.​4065/​78.​6.​696 PubMedCrossRef
22.
go back to reference Alloussi S, Murtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rossler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Bock P, Strugala G, Madersbacher H (2010) Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int 106:550–556. doi:10.1111/j.1464-410X.2009.09129.x PubMedCrossRef Alloussi S, Murtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rossler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Bock P, Strugala G, Madersbacher H (2010) Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int 106:550–556. doi:10.​1111/​j.​1464-410X.​2009.​09129.​x PubMedCrossRef
Metadata
Title
Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia
Authors
Minki Baek
Jung Yoon Kang
Jeongyun Jeong
Dae Kyung Kim
Kwang Myung Kim
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0423-1

Other articles of this Issue 3/2013

International Urology and Nephrology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.